Further Lipid-Lowering With PCSK9 Inhibitors for Cardiovascular Outcomes in High-Risk Coronary Plaques Assessed by CT Angiography

Other illness

• Patients with acute coronary syndrome.
• Active liver disease or hepatic dysfunction.
• Known hypersensitivity or contraindication to statin or PCSK9 inhibitors.

Lab values

• New York Heart Association class III or IV, or last known left ventricular ejection fraction \< 30%.

Age

• Non-cardiac co-morbid conditions with life expectancy \< 2 years.

Other

• Target lesions underwent or planned to revascularization.
• Uncontrolled or recurrent ventricular tachycardia.
• Homozygous familial hypercholesterolemia.
• Failed CCTA plaque analysis.
• Pregnant and/or lactating women.

• Subject must be ≥ 18 years.
• Patients with at least one target lesion meet CCTA-detected plaque features of the following:
  • Degree of stenosis ≥ 50% or plaque burden ≥ 70%
  • At least 2 of the following high-risk plaque features:
  • Low-attenuation plaque ii. Positive remodeling iii. Napkin-ring sign iv. Spotty calcium
• The target lesion is located at the proximal or mid segment of left anterior descending artery, left circumflex artery or right coronary artery.
• Subject is able to confirm his/her understanding of the risks, benefits, and treatment alternatives of receiving study-related treatment. He/she or his/her legally authorized representative provides written informed consent prior to any study-related procedure.